Top Washington DC, Biotech Companies (45)
.png)
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products
For 60 years, HHMI has been moving science forward. We’re an independent, ever-evolving philanthropy that supports basic biomedical scientists and science educators with the potential for transformative impact. We invest in people, not projects. We encourage collaborative and results-driven working styles and offer an adaptable environment where employees can function at their highest level. As HHMI scientists continue to push boundaries in laboratories and classrooms, you can be sure that your contributions while working at HHMI are making a difference. To move science forward, we need experts in areas such as communications, finance, human resources, information technology, investments, and law as well as scientists. Visit our website at http://www.hhmi.org
We're hiring! ZERO TO THREE is a national nonprofit organization that informs, trains and supports professionals, policymakers and parents in their efforts to improve the lives of infants and toddlers. Neuroscientists have documented that our earliest days, weeks and months of life are a period of unparalleled growth when trillions of brain cell connections are made. Research and clinical experience also demonstrate that health and development are directly influenced by the quality of care and experiences a child has with his parents and other adults. That is why at ZERO TO THREE our mission is to ensure all babies and toddlers have a strong start in life. We know that as babies, the way we are held, talked to and cared for teaches us about who we are and how we are valued. This profoundly shapes who we will become. Early experiences set a course for a lifelong process of discovery about ourselves and the world around us. Simply put, early experiences matter. We encourage you to learn more about very young children, early development and the work of ZERO TO THREE by exploring our site. Explore opportunities at zerotothree.org/careers
Computercraft, an American Indian– and Woman-owned small business, provides the public with user-friendly access to reliable and current genetic sequence, genomic, chemical, and scientific information. Our technical and scientific staff work with customers to build and refine high-profile information resources that get accurate health and biomedical research data into the hands of researchers and other stakeholders all over the globe, helping them solve our world’s greatest health challenges. In some of our other work, we provide program management support and health communication and outreach that directly and indirectly facilitate and sustain our nation's public health efforts
Official account of the National Center for Biotechnology Information (NCBI) at the National Library of Medicine. NCBI serves as an international resource for the scientific research community - providing access to public databases and software tools for analyzing biological data, as well as performing research in computational biology. The NCBI was established in 1988 by an act of the United States Congress as division of the National Library of Medicine at the National Institutes of Health, with a mission to find new approaches to deal with the increasing volume and complexity of biological data in order to facilitate the understanding of genes and their role in health and disease. The NCBI is made up of multidisciplinary research and development teams composed of molecular biologists, biochemists, structural biologists, clinicians, mathematicians, and computer scientists who: Archive: Gather scientific and medical research data from around the globe • Serve as the largest repository of the world’s primary biological research data • Produce curated datasets to enhance the value and usability of the primary data Access: Develop systems for discovering and integrating scientific and medical data • Create search tools and data cross-referencing mechanisms • Display and enable download of information from the world's largest collection of biological data Advance: Promote understanding of processes that effect health and disease • Perform cutting-edge research in computational biology • Design and build algorithms, programs and systems for analysis of biological data • Provide support and training through a varied and vigorous outreach program
We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies.
Medcura, Inc. has developed an advanced wound care platform that can be used across a broad spectrum of clinical and non-clinical settings. By making molecular modifications to natural biopolymers, gel-e’s patented approach provides rapid hemostasis in a clean, safe healing environment. The company has achieved milestones such as 3 FDA Clearances, 6 issued patents, and 7 peer-reviewed publications.
NuPulse is a medical device company developing novel technology to treat patients with heart failure.
Founded in 1995, Meso Scale Discovery (MSD) is a global leader in the development, manufacture, and commercialization of innovative assays and instruments for the measurement of molecules in biological samples. MSD’s proprietary MULTI ARRAY technology enhances medical research and drug development by enabling researchers to profile many biomarkers simultaneously in a single sample without compromising assay performance. MSD’s technology has been widely adopted by researchers in pharmaceutical companies, government institutions, universities, and clinical laboratories worldwide for its high sensitivity, excellent reproducibility, and wide dynamic range. Throughout its history, MSD has continued to evolve its technology platform to enable researchers to solve complex biological questions and, as the Company looks toward the future, it is expanding into clinical applications and the emerging fields of personalized medicine and companion diagnostics.
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world’s first and only chikungunya vaccine, as well as certain third-party vaccines. Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. with approximately 700 employees.
Quality Biological (QBI) provides quality solutions for life science research and bioproduction applications. We specialize in producing custom and standard cell culture and molecular biology reagents, buffers, and liquid solutions and providing supporting services. At QBI, we help our clients achieve their application goals faster. We do this by being flexible and nimble, providing a level of personalized service our clients rely on. QBI is home to a fully-equipped, ISO 9001:2015 certified manufacturing facility. At the base of every product is water that exceeds industry specifications. This enables us to provide you with solutions of superior quality and value. We have your solution...whether you need a few liters of medium, buffer or a custom solution for research, dozens of liters of one single lot for process and method validation, or hundreds of liters for commercialization. We work with you to address your specific needs and requirements. Contact us today to discuss your specific media and buffer needs.
ScripsAmerica distributes pharmaceutical products, including pain, arthritis, prenatal, urinary, and hormonal replacement drugs.
54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market; Nearly 90% of genetic material used in pharmaceutical research is Caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions.
OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based tools have enabled the identification of relevant drug targets through system biology approaches. OriGene's vision is to prepare comprehensive, genome-wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research. OriGene Technologies uses high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research. Our flagship product is the cDNA clone collection, a searchable gene bank of over 30,000 human full-length TrueClone cDNA collections and over 25,000 TrueORF cDNA clones. From our TrueORF cDNA clones, we have developed the largest offering of full-length human proteins expressed in mammalian cells, ideal for functional studies. In 2010, OriGene initiated the TrueMAB project to develop mouse monoclonal antibodies against protein antigens to develop protein assays for every human protein. In addition, OriGene offers unique gene expression products such as TissueScan cancer tissue qPCR arrays and tissue biorepository for biomarker discovery and validation OriGene is committed to its mission to be “Your Gene Company”, supplying everything a researcher needs for gene-based research. Visit us at https://www.origene.com
Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT’s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.
Vanda Pharmaceuticals (NASDAQ: VNDA) is a biopharmaceutical company focused on the development and commercialization of products for the
GeneCopoeia, Inc. is a leading provider and manufacture of genomics and proteomics products and services worldwide. GeneCopoeia has developed a series of cutting edge research tools, including the largest collection of expression-ready clones (ORF cDNA, Promoter, shRNA, miRNA), comprehensive genome-editing tools (CRISPR and TALEN), as well as highly efficient viral delivery systems (Lentivirus and AAV). In addition to its genomics and proteomics products, GeneCopoeia also offers fluorescent detection reagents (e.g. non-toxic DNA gel stains, protein gel stains, cell biology assay kits, labeling dyes and antibodies), as well as other molecular biology reagents and kits (e.g. luciferase assay kits, qPCR arrays and products, transfection reagents and more).
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™, and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.
I-Mab (Nasdaq: IMAB) is an innovation-driven global biopharma company focused on the discovery, development and commercialization of novel and highly differentiated biologics for immuno-oncology. The company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's globally competitive pipeline of more than 20 clinical and preclinical-stage drug candidates is driven by its internal discovery and global partnerships for in-licensing, based on the company's Fast-to-Proof-of-Concept and Fast-to-Market development strategies. The company is progressing from a clinical-stage biotech company into a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, a world-class GMP manufacturing facility, and commercial capability. I-Mab has its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong, and in Gaithersburg, Maryland, and San Diego, California.
Work Your Passion. Live Your Purpose.
